Back to search
FDAFDA · Food and drugs·Recall number D-0149-2017

BuPROPion Hydrochloride Extended-Release Tablets, USP (XL) 300 mg, Rx Only, 500-count bottles, Manufactured by Cadila Healthcare Ltd. Ahmedabad, India Distributed by: Zydus Pharmaceuticals USA inc. Pennington, NJ 08534, NDC 68382-354-05

Published November 30, 2016 · Recall initiated: August 3, 2016

Summary

FDA records drug Class III recall D-0149-2017, published November 30, 2016 and initiated August 3, 2016. Recalling firm: Zydus Pharmaceuticals USA Inc; Status: Terminated; Reported quantity: 2,472 units; Lot: Lot #: MR3365, Exp. Feb 17. Class III means the product is not likely to cause adverse health consequences.

Status when published: Terminated — openFDA updates weekly, so this field may not reflect the current status. Always confirm with the official notice.

What's the hazard

Failed Dissolution Specifications: Product did not meet dissolution specification at an intermediate time point.

What to do

Voluntary: Firm initiated · Letter

Get an email if BUPROPION has another recall

Free. We only write when there's a new recall that matches. Unsubscribe in one click.

Recall details

Brand
BUPROPION
Manufacturer
Zydus Pharmaceuticals USA Inc
Distributor
Nationwide
Lot
Lot #: MR3365, Exp. Feb 17
Risk classification
Class III
Area (FDA)
drug
Country
United States

Related recalls

Questions about this recall

Was BuPROPion Hydrochloride Extended-Release Tablets, USP (XL) 300 mg, Rx Only, 500-count bottles, Manufactured by Cadila Healthcare Ltd. Ahmedabad, India Distributed by: Zydus Pharmaceuticals USA inc. Pennington, NJ 08534, NDC 68382-354-05 recalled?

Yes. FDA published recall D-0149-2017 on November 30, 2016. Reported hazard: Failed Dissolution Specifications: Product did not meet dissolution specification at an intermediate time point.

What should I do if I have this product?

Voluntary: Firm initiated · Letter

How do I know if my unit is part of the recall?

Compare your product details with the notice. Brand: BUPROPION.